ARROWHEAD PHARMACEUTICALS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
ARROWHEAD PHARMACEUTICALS INC. - More news...
ARROWHEAD PHARMACEUTICALS INC. - More news...
- Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
- Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals?
- Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
- Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
- First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
- Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
- Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
- Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
- Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
- Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
- Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
- Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
- Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
- Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
- Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
- Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
- Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
- Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
